News

April 14, 2017 - Altor Bioscience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor’s IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trial Read More

March 31, 2017 - DalCor Pharmaceuticals to Present at Needham & Co. Healthcare Conference Read More

March 10, 2017 - Hill Pharmacy Announces Training Closures, Kiosk Option Read More

March 9, 2017 - ViaCyte and W. L. Gore & Associates Announce Collaborative Research Agreement to Develop Novel Implantable Delivery Technologies for Cell Therapies Read More

March 7, 2017 - Sanderling Ventures Announces the Acquisition of Torax Medical by Ethicon Read More

March 7, 2017 - Ethicon Announces Completion Of Acquisition Of Torax Medical, Inc. Read More

March 7, 2017 - DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule — Dalcetrapib Studied in Genetically Distinct Patients with Acute Coronary Syndrome Read More

February 23, 2017 - Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapies for Type 1 Diabetes Read More

February 21, 2017 - ViaCyte to Present at Four Upcoming Healthcare Events Read More

January 25, 2017 - Johns Hopkins and AAMI publish on implementation of ViSi Mobile System Read More